{"format":{"id":"cell-therapy","name":"Other cell therapies","blurb":"Cells without an engineered receptor: tumour-infiltrating lymphocytes, natural killer cells, cord blood grafts and virus-specific T cells, from the patient or from a donor.","axes":["cellType","cellSource"],"axisLabels":["Cell type","Cell source"],"components":[{"key":"cellType","label":"Cell type"},{"key":"cellSource","label":"Cell source"}]},"counts":{"approved":5,"development":0,"stopped":0,"unclear":0,"untried":6,"drugs":9,"partial":2,"unresolved":1},"coverage":{"total":10,"full":7,"partial":2,"unresolved":1,"pct":90},"rows":[{"key":"cellType","id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/"},{"key":"cellType","id":"cord-blood-hsc","name":"Cord blood stem cells","href":"/technologies/allogeneic-hsct/"},{"key":"cellType","id":"nk","name":"NK cell","href":"/technologies/nk-cell-therapy/"},{"key":"cellType","id":"msc","name":"Mesenchymal stromal cells"},{"key":"cellType","id":"virus-specific-t","name":"Virus-specific T cells","href":"/technologies/virus-specific-t-cells/"}],"cols":[{"key":"cellSource","id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/"},{"key":"cellSource","id":"autologous","name":"Autologous"},{"key":"cellSource","id":"not-recorded","name":"Cell source not recorded"}],"cells":[{"a":{"key":"cellType","id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/"},"b":{"key":"cellSource","id":"autologous","name":"Autologous"},"state":"approved","drugs":[{"id":"gc101-til","name":"GC101 TIL","route":"/drugs/gc101-til/","state":"development","status":"phase-2"},{"id":"lifileucel","name":"Lifileucel","route":"/drugs/lifileucel/","state":"approved","status":"approved"},{"id":"tacquell","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/","state":"stopped"}],"counts":{"approved":1,"development":1,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"gc101-til","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/gc101-til/"},{"record":"nct07560111","field":"status","kind":"trial","state":"development","label":"A Phase II Study of GC101 in NSCLC: phase 2, recruiting","href":"/trials/nct07560111/"},{"record":"nct06703398","field":"status","kind":"trial","state":"development","label":"A Study of GC101 TIL in Advanced Melanoma: phase 2, recruiting","href":"/trials/nct06703398/"},{"record":"registry:gc101-til","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/gc101-til/#registry"},{"record":"lifileucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lifileucel/"},{"record":"lifileucel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Unresectable/metastatic melanoma after anti-PD-1 (and BRAF/MEK if applicable)","href":"/drugs/lifileucel/"},{"record":"lifileucel","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"lifileucel","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi","quote":"MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)"},{"record":"nct06481592","field":"status","kind":"trial","state":"development","label":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.: phase 2, recruiting","href":"/trials/nct06481592/"},{"record":"nct07288203","field":"status","kind":"trial","state":"development","label":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma: phase 2, active","href":"/trials/nct07288203/"},{"record":"registry:lifileucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lifileucel/#registry"},{"record":"tacquell","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma"},{"record":"tacquell","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"EU 2026-06-25: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","quote":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute"}],"reasons":[{"drugId":"lifileucel","drugName":"Lifileucel","drugRoute":"/drugs/lifileucel/","drugState":"approved","record":"lifileucel","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi","quote":"MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)"},{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma"},{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"event","label":"EU 2026-06-25: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","quote":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute"}]},{"a":{"key":"cellType","id":"cord-blood-hsc","name":"Cord blood stem cells","href":"/technologies/allogeneic-hsct/"},"b":{"key":"cellSource","id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/"},"state":"approved","drugs":[{"id":"dorocubicel","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","state":"approved","status":"approved"},{"id":"omidubicel","name":"Omidubicel","route":"/drugs/omidubicel/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"dorocubicel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dorocubicel/"},{"record":"dorocubicel","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2025: Adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no other suitable donor cells","href":"/drugs/dorocubicel/"},{"record":"dorocubicel","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemcelpro"},{"record":"omidubicel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/omidubicel/"},{"record":"omidubicel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Adults and children aged 12 and over with haematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning, to reduce time to neutrophil recovery and infection","href":"/drugs/omidubicel/"},{"record":"registry:omidubicel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/omidubicel/#registry"}],"reasons":[]},{"a":{"key":"cellType","id":"nk","name":"NK cell","href":"/technologies/nk-cell-therapy/"},"b":{"key":"cellSource","id":"not-recorded","name":"Cell source not recorded"},"state":"approved","drugs":[{"id":"aldesleukin","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","state":"approved","status":"approved"},{"id":"cd19-t-hank","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","state":"development","status":"phase-2"}],"counts":{"approved":1,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"aldesleukin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1992: Metastatic renal cell carcinoma","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Metastatic melanoma","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1992","href":"/regulatory/regions/"},{"record":"aldesleukin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"/regulatory/regions/"},{"record":"aldesleukin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Proleukin"},{"record":"aldesleukin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Proleukin"},{"record":"nct07681596","field":"status","kind":"trial","state":"development","label":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma: phase 1/2, recruiting","href":"/trials/nct07681596/"},{"record":"nct06119685","field":"status","kind":"trial","state":"development","label":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: phase 1/2, recruiting","href":"/trials/nct06119685/"},{"record":"nct05267626","field":"status","kind":"trial","state":"development","label":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca: phase 1/2, recruiting","href":"/trials/nct05267626/"},{"record":"registry:aldesleukin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/aldesleukin/#registry"},{"record":"cd19-t-hank","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cd19-t-hank/"},{"record":"nct07125872","field":"status","kind":"trial","state":"development","label":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma: phase 2, recruiting","href":"/trials/nct07125872/"},{"record":"registry:cd19-t-hank","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/cd19-t-hank/#registry"}],"reasons":[]},{"a":{"key":"cellType","id":"msc","name":"Mesenchymal stromal cells"},"b":{"key":"cellSource","id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/"},"state":"approved","drugs":[{"id":"remestemcel-l","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"remestemcel-l","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/remestemcel-l/"},{"record":"remestemcel-l","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Steroid-refractory acute graft-versus-host disease in children aged two months and older","href":"/drugs/remestemcel-l/"},{"record":"registry:remestemcel-l","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/remestemcel-l/#registry"}],"reasons":[]},{"a":{"key":"cellType","id":"virus-specific-t","name":"Virus-specific T cells","href":"/technologies/virus-specific-t-cells/"},"b":{"key":"cellSource","id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/"},"state":"approved","drugs":[{"id":"tabelecleucel","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"tabelecleucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tabelecleucel/"},{"record":"tabelecleucel","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2022: Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy","href":"/drugs/tabelecleucel/"},{"record":"nct03394365","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu: phase 3, recruiting","href":"/trials/nct03394365/"},{"record":"nct04554914","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases: phase 2, active","href":"/trials/nct04554914/"},{"record":"registry:tabelecleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/tabelecleucel/#registry"}],"reasons":[]}],"components":{"cellType":[{"key":"cellType","id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/","count":3,"drugIds":["gc101-til","lifileucel","tacquell"],"states":{"approved":1,"development":1,"stopped":1,"unclear":0}},{"key":"cellType","id":"cord-blood-hsc","name":"Cord blood stem cells","href":"/technologies/allogeneic-hsct/","count":2,"drugIds":["dorocubicel","omidubicel"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"cellType","id":"nk","name":"NK cell","href":"/technologies/nk-cell-therapy/","count":2,"drugIds":["aldesleukin","cd19-t-hank"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}},{"key":"cellType","id":"msc","name":"Mesenchymal stromal cells","count":1,"drugIds":["remestemcel-l"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"cellType","id":"virus-specific-t","name":"Virus-specific T cells","href":"/technologies/virus-specific-t-cells/","count":1,"drugIds":["tabelecleucel"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"cellSource":[{"key":"cellSource","id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/","count":4,"drugIds":["dorocubicel","omidubicel","remestemcel-l","tabelecleucel"],"states":{"approved":4,"development":0,"stopped":0,"unclear":0}},{"key":"cellSource","id":"autologous","name":"Autologous","count":3,"drugIds":["gc101-til","lifileucel","tacquell"],"states":{"approved":1,"development":1,"stopped":1,"unclear":0}}]},"drugs":[{"id":"aldesleukin","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","status":"approved","modality":"Recombinant interleukin-2 (cytokine)","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"nk","name":"NK cell","href":"/technologies/nk-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"aldesleukin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1992: Metastatic renal cell carcinoma","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Metastatic melanoma","href":"/drugs/aldesleukin/"},{"record":"aldesleukin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1992","href":"/regulatory/regions/"},{"record":"aldesleukin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"/regulatory/regions/"},{"record":"aldesleukin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Proleukin"},{"record":"aldesleukin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Proleukin"},{"record":"nct07681596","field":"status","kind":"trial","state":"development","label":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma: phase 1/2, recruiting","href":"/trials/nct07681596/"},{"record":"nct06119685","field":"status","kind":"trial","state":"development","label":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: phase 1/2, recruiting","href":"/trials/nct06119685/"},{"record":"nct05267626","field":"status","kind":"trial","state":"development","label":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca: phase 1/2, recruiting","href":"/trials/nct05267626/"},{"record":"registry:aldesleukin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/aldesleukin/#registry"}],"reasons":[]},{"id":"cd19-t-hank","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","status":"phase-2","modality":"cell therapy (type not stated)","state":"development","confidence":"high","fields":["modality","mechanism","targets"],"components":{"cellType":{"id":"nk","name":"NK cell","href":"/technologies/nk-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"cd19","name":"CD19","href":"/targets/cd19/","confidence":"high","from":["targets"],"detail":null}},"evidence":[{"record":"cd19-t-hank","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cd19-t-hank/"},{"record":"nct07125872","field":"status","kind":"trial","state":"development","label":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma: phase 2, recruiting","href":"/trials/nct07125872/"},{"record":"registry:cd19-t-hank","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/cd19-t-hank/#registry"}],"reasons":[]},{"id":"dorocubicel","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","status":"approved","modality":"Allogeneic expanded cord blood cell therapy (ATMP)","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"cord-blood-hsc","name":"Cord blood stem cells","href":"/technologies/allogeneic-hsct/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dorocubicel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dorocubicel/"},{"record":"dorocubicel","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2025: Adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no other suitable donor cells","href":"/drugs/dorocubicel/"},{"record":"dorocubicel","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemcelpro"}],"reasons":[]},{"id":"gc101-til","name":"GC101 TIL","route":"/drugs/gc101-til/","status":"phase-2","modality":"TIL therapy","state":"development","confidence":"high","fields":["modality","mechanism","targets"],"components":{"cellType":{"id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null},"target":{"id":"pd1+braf+mek","name":"PD-1 x BRAF x MEK1/2","href":"/targets/pd1/","confidence":"high","from":["targets"],"detail":"dual-target"}},"evidence":[{"record":"gc101-til","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/gc101-til/"},{"record":"nct07560111","field":"status","kind":"trial","state":"development","label":"A Phase II Study of GC101 in NSCLC: phase 2, recruiting","href":"/trials/nct07560111/"},{"record":"nct06703398","field":"status","kind":"trial","state":"development","label":"A Study of GC101 TIL in Advanced Melanoma: phase 2, recruiting","href":"/trials/nct06703398/"},{"record":"registry:gc101-til","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/gc101-til/#registry"}],"reasons":[]},{"id":"lifileucel","name":"Lifileucel","route":"/drugs/lifileucel/","status":"approved","modality":"TIL cell therapy","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lifileucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lifileucel/"},{"record":"lifileucel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Unresectable/metastatic melanoma after anti-PD-1 (and BRAF/MEK if applicable)","href":"/drugs/lifileucel/"},{"record":"lifileucel","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"lifileucel","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi","quote":"MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)"},{"record":"nct06481592","field":"status","kind":"trial","state":"development","label":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.: phase 2, recruiting","href":"/trials/nct06481592/"},{"record":"nct07288203","field":"status","kind":"trial","state":"development","label":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma: phase 2, active","href":"/trials/nct07288203/"},{"record":"registry:lifileucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/lifileucel/#registry"}],"reasons":[{"drugId":"lifileucel","drugName":"Lifileucel","drugRoute":"/drugs/lifileucel/","drugState":"approved","record":"lifileucel","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi","quote":"MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)"}]},{"id":"omidubicel","name":"Omidubicel","route":"/drugs/omidubicel/","status":"approved","modality":"Nicotinamide-expanded allogeneic cord blood cell therapy","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"cord-blood-hsc","name":"Cord blood stem cells","href":"/technologies/allogeneic-hsct/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"omidubicel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/omidubicel/"},{"record":"omidubicel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Adults and children aged 12 and over with haematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning, to reduce time to neutrophil recovery and infection","href":"/drugs/omidubicel/"},{"record":"registry:omidubicel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/omidubicel/#registry"}],"reasons":[]},{"id":"remestemcel-l","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","status":"approved","modality":"Allogeneic bone marrow-derived mesenchymal stromal cell therapy","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"msc","name":"Mesenchymal stromal cells","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"remestemcel-l","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/remestemcel-l/"},{"record":"remestemcel-l","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Steroid-refractory acute graft-versus-host disease in children aged two months and older","href":"/drugs/remestemcel-l/"},{"record":"registry:remestemcel-l","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/remestemcel-l/#registry"}],"reasons":[]},{"id":"tabelecleucel","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","status":"approved","modality":"Cell therapy: allogeneic off-the-shelf Epstein-Barr virus-specific T cells","state":"approved","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"virus-specific-t","name":"Virus-specific T cells","href":"/technologies/virus-specific-t-cells/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"allogeneic","name":"Allogeneic","href":"/technologies/allogeneic-cell-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tabelecleucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tabelecleucel/"},{"record":"tabelecleucel","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2022: Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy","href":"/drugs/tabelecleucel/"},{"record":"nct03394365","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu: phase 3, recruiting","href":"/trials/nct03394365/"},{"record":"nct04554914","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases: phase 2, active","href":"/trials/nct04554914/"},{"record":"registry:tabelecleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/tabelecleucel/#registry"}],"reasons":[]},{"id":"tacquell","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/","status":null,"modality":"TIL cell therapy (autologous tumour-infiltrating lymphocytes, ex vivo expanded)","state":"stopped","confidence":"high","fields":["modality","mechanism"],"components":{"cellType":{"id":"til","name":"Tumour-infiltrating lymphocytes","href":"/technologies/til-therapy/","confidence":"high","from":["modality","mechanism"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tacquell","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma"},{"record":"tacquell","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"EU 2026-06-25: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","quote":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute"}],"reasons":[{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma"},{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"event","label":"EU 2026-06-25: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","quote":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute"}]}],"unresolved":[{"id":"tara-002","name":"TARA-002","route":"/drugs/tara-002/","format":"cell-therapy","modality":"cell therapy (type not stated)","missing":["cellType","cellSource"],"why":"No cell type on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 25 Jun 2026 on Tacquell (autologous TIL; applicant Netherlands Cancer Institute) for melanoma"},{"drugId":"tacquell","drugName":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","drugRoute":"/drugs/tacquell/","drugState":"stopped","record":"tacquell","kind":"event","label":"EU 2026-06-25: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell","quote":"CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute"},{"drugId":"lifileucel","drugName":"Lifileucel","drugRoute":"/drugs/lifileucel/","drugState":"approved","record":"lifileucel","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi","quote":"MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing)"}],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}